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ABSTRACT:
Breast cancer is a leading form of cancer in the world. The Drosophila Dac 
gene was cloned as an inhibitor of the hyperactive epidermal growth factor (EGFR), 
ellipse. Herein, endogenous DACH1 co-localized with p53 in a nuclear, extranucleolar 
compartment and bound to p53 in human breast cancer cell lines, p53 and DACH1 
bound common genes in Chip-Seq. Full inhibition of breast cancer contact-independent 
growth by DACH1 required p53. The p53 breast cancer mutants R248Q and R273H, 
evaded DACH1 binding. DACH1 phosphorylation at serine residue (S439) inhibited 
p53 binding and phosphorylation at p53 amino-terminal sites (S15, S20) enhanced 
DACH1 binding. DACH1 binding to p53 was inhibited by NAD-dependent deacetylation 
via DACH1 K628. DACH1 repressed p21CIP1 and induced RAD51, an association found 
in basal breast cancer. DACH1 inhibits breast cancer cellular growth in an NAD and 
p53-dependent manner through direct protein-protein association.  
INTRODUCTION
Breast cancer is one of the leading causes of 
cancer mortality in women worldwide, with an estimated 
232,340 new cases in 2013 in the United States. p53 is 
the most frequent target for mutation in tumors, occurring 
predominantly as missense mutations, several of which 
occur as “hot spot” mutations in the DNA-binding 
core domain [1]. In the cellular environment without 
DNA damaging or oncogenic stress, p53 is short lived. 
Activation of p53 in response to cellular stress contributes 
to the induction of cell cycle arrest, cellular senescence 
and apoptosis, and cellular differentiation. Missense 
mutations lead to the accumulation of p53 mutant 
protein, which in humans correlates with poor outcome 
in a variety of human tumors, including breast cancer [2]. 
The R248Q missense mutant in particular is associated 
with poor prognosis in breast cancer [2]. The function 
of p53 is modulated through altered cellular localization 
and post-translational modifications [3] , which recruit 
protein complexes to coordinate gene expression and 
control cellular phenotype. Understanding the mechanisms 
governing p53 function via its associated protein binding 
partners is fundamental to tumor biology. 
Initially cloned as a dominant inhibitor of the 
hyperactive EGFR, Ellipse, in Drosophila, the mammalian 
DACH1 regulates expression of target genes in part 
through interacting with DNA-binding transcription 
factors (c-Jun, Smads, Six, ERα), and in part through 
intrinsic DNA-sequence specific binding to Forkhead 
binding sites [4-7]. The Drosophila dac gene is a key 
member of the retinal determination gene network 
(RDGN), which also includes eyes absent (eya), ey, twin 
of eyeless (toy), teashirt (tsh) and sin oculis (so), that 
specifies eye tissue identity. 
Several lines of evidence suggest DACH1 may 
function as a tumor suppressor. Clinical studies have 
demonstrated a correlation between poor prognosis 
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and reduced expression of the cell-fate determination 
factor DACH1 in breast cancer [7], and loss of DACH1 
expression has been observed in prostate and endometrial 
cancer [6, 8]. DACH1 inhibits breast cancer tumor 
metastasis and reduces breast cancer stem cell expansion 
via Sox2/Nanog [9]. Although these studies suggest 
DACH1 may function as a tumor suppressor, the 
molecular mechanisms remain poorly defined.
Given the importance of p53 as a tumor suppressor 
in human breast cancer, we examined the role of DACH1 
in p53-mediated breast cancer cellular growth suppression. 
These studies identified DACH1 as a novel p53 binding 
protein that enhances p53 WT tumor suppressor function. 
DACH1 is shown to be acetylated at its carboxyl terminus, 
which governs p53 binding and function.
RESULTS
DACH1 associates with p53 in human breast 
cancer cells. 
In order to determine whether DACH1 associates 
with p53, we first examined the association of endogenous 
p53 with DACH1 using the MDA-MB-453 breast cancer 
cell line, which express wild-type p53. DACH1 was 
localized using a previously well characterized monoclonal 
DACH1 antibody [7], in a nuclear, extranucleolar location 
(S. 1A). p53 was in both nuclear and nucleolar location, 
and co-localized with DACH1 (S. 1A) (high resolution 
merged image, S. 2). 
To further confirm the association between p53 and 
DACH1, immunoprecipitation (IP) –Western blotting 
(WB) was conducted using an antibody, either to p53 with 
sequential WB to DACH1, or immunoprecipitation with 
a DACH1 specific antibody and sequential WB for p53 
(S. 1B). In both IP-WB approaches, p53 associated with 
DACH1. In order to determine the domains of DACH1 
required for association with p53, the alternate spliced 
forms of DACH1 (DACH1b, 1c) were expressed with 
wild-type DACH1a in HEK 293T cells. IP-WB was 
conducted. WB demonstrated the presence of DACH1a, 
1b, 1c (S. 1C) and IP-WB revealed DACH1 using anti-
FLAG and the association with p53 using a p53 specific 
antibody (S. 1C). We extended these studies to examine 
the association between DACH1 and p53 in other breast 
cancer cell lines. Immunoflourescent analysis of DACH1 
and p53 in MCF-7 cells demonstrated the co-localization 
of p53 and DACH1 in an intranuclear extranucleolar 
location through a merged image (S. 1D). IP-WB with an 
anti-FLAG antibody directed towards the amino terminal 
FLAG epitope of DACH1 revealed its association with 
p53 (S. 1E). In MDA-MB-231 cells, which have low 
levels of endogenous DACH1, the stable reintroduction 
of DACH1 under control of a ponasterone-regulated 
promoter demonstrated that p53 and DACH1 associated 
in an intranuclear extranucleolar location merged upon the 
induction of DACH1 by (S. 1F).
DACH1 binding to p53 is abrogated by p53 hot 
spot mutations and p53 acetylation at K120.
We next considered the possibility that specific 
residues within p53 may determine physical association 
with DACH1. In order to identify the domains of p53 
required for binding to DACH1, a series of expression 
vectors were deployed encoding p53 “hot spot” point 
mutations identified in breast cancer. The N-terminal 
FLAG epitope was used to immunoprecipitate DACH1 (S. 
3A). Western blot analysis demonstrated the association 
of endogenous p53 with DACH1. DACH1 showed 
wild-type binding to R175H, the mutant found in MDA-
MB-231 cells [10].  The R248Q and R273H are “hot 
spot” mutations in breast cancer that are located in the 
DNA-binding domain and central core region. Binding 
of DACH1 to the R273H mutant was reduced 60% and 
the R248Q mutant was incapable of binding DACH1 (S. 
3A,B). 
As p53 function is regulated by phosphorylation, we 
examined a panel of p53 phosphorylation site mutations 
(S. 3C). Mutation of Serine 15 and Serine 20 reduced 
DACH1 binding by > 40% (S. 3C,D). Post-translational 
modification of p53 by acetylation contributes to p53-
dependent growth arrest and apoptosis, without affecting 
p53-MDM2-dependent feedback [11]. p53 acetylation 
within the carboxyl-terminus contributes to the DNA 
damage response [12, 13]. p53 acetylation within the DNA 
binding domain at K120 selectively enhances the ability 
of p53 to regulate apoptosis by altering DNA binding to 
selective targets [14-16]. In multiple experiments, the 
p53 acetylation site mutant K120R showed significantly 
enhanced binding to DACH1 (S. 3E,F). The polymorphic 
residue, Proline 72, which is located in the transactivation 
domain 2, reduced DACH1 binding (S. 3G,H). Mutation 
of the carboxyl-terminal module of acetylation sites (p53 
9K/R) caused no significant change in DACH1 binding 
(Fig. S3G,H), while the 9K/R, K120R showed enhanced 
binding (S. 3H). A schematic representation summarizing 
the residues of p53 residues, mutated in human breast 
cancer and the K120 site for DACH1 binding, are shown 
in S. 3I.
Common genes are regulated by and bind DACH1 
and p53 in the context of local chromatin.
DACH1-regulated genes identified using gene 
expression analysis [17] were compared with p53-
regulated genes. Three gene expression microarray 
datasets profiling DACH1 responsive genes were used for 
analysis (DACH1.0hr, DACH1.18h, DACH1.36h [17], 
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Figure 1: p53 and DACH1 regulate common functional gene modules and bind common genes in ChIP-Seq. (A-B) 
Molecular pathways enriched with genes regulated by DACH1 and p53.  Pathways enriched with induced genes are represented by red bars. 
Pathways enriched with repressed genes are represented by green bars.  ES score is equal to the confidence of enrichment expressed as –
log(p). (C) Number of genes co-regulated by DACH1 and p53. X = genes upregulated by both DACH1 and p53. Y = genes downregulated 
by both DACH1 and p53. (D) Pie diagram of overlapping genes binding DACH1 and p53 in ChIP-Seq. (E) Cumulative distribution of the 
location of Chip-Seq peaks with respect to neighboring genes.   (F) Histogram of the location of DACH1 and p53 Chip-Seq peaks relative 
to the transcription start site (TSS) at -10 kb to +50 kb (upper panel) and -1 kb to +1 kb (lower panel).  (G) Integrated genome browser 
visualization of tag density profiles for ChIP-Seq DACH1 and ChIP-Seq p53.  Selected genes are PARD6B, par-6 partitioning defective 6 
homolog beta and FAM84B, family with sequence similarity 84, member B.
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Figure 2: DACH1 enhances p53-dependent inhibition of colony formation and induction of apoptosis. (A-B) MTT assay 
of proliferation in MCF-7 cells expressing either DACH1 or DACH1 ΔC in the presence of either control or shRNA to p53. (C) Western blot 
for p53 and DACH1 (identified by the FLAG tag). (D-I) Colony formation assays using MCF-7 cells expressing either wild-type DACH1 
or ΔC in the presence of control or shRNA to p53 (D,E), representative examples of colonies formed and (F-I) quantification of data shown 
as mean ± SEM. In (J-L) analysis of MCF-7 cells stably expressing DACH1 and shp53 for (J) S-phase of the cell-cycle (K), sub-G1 and (L) 
Annexin V staining as a marker of apoptosis.
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mRNA). The function of genes that are regulated by either 
DACH1 or p53 were assessed (Fig. 1A,B). Functional 
enrichment analysis using pathways obtained from the 
molecular signatures database indicated a set of common 
Figure 3: NAD-dependent binding of DACH1 to p53. (A) A peptide encoding the candidate DACH1 acetylation site (626 
VQKRLKKEKKAKRKLQEAL 644) was incubated with p300 as an enzyme source in the presence of acetyl CoA. Acetylation products 
were purified with reverse-phase HPLC followed by MALDI-TOF mass spectrometry (A) and then sequenced by Edman degradation. In 
(A), the resulting DACH1 peptide (DACH1aa 626-644) mass spectrum is shown with mass/charge expressed in atomic mass units (amu). 
The major peaks labeled X corresponds to the expected mass of DACH1 whereas the large peak Y, is larger by 42 mass units, representing 
a single acetylated peptide. In (B) the bars represent the amount of phenylthiohydantoin-acetyl-lysine present in the corresponding position. 
The major acetylated product corresponds to residue K628. The inset shows an alignment of the DACH1 sequence and the acetylated 
residue motif seen in other acetylated transcription factors and the corresponding consensus sequence KX(x)KK. (C) IP-WB of HEK293T 
cells transfected with expression vectors encoding p53 or DACH1 and subsequently treated with Nicotinamide (NAM 20 mM) and/or 
Trichostatin A (TSA 2μm) for 8hrs. (D) Western blot of lysates corresponding to IP-Western in (C). (E) Relative binding of DACH1 to p53 
shown as mean ± SEM for 3 separate experiments. IP-Western blot of MDA-MB-453 cells treated with TSA (2 μM) or NAM (20 mM) 
showing (G) relative binding of p53 to DACH1 (data are mean ± SEM for 3 separate experiments).
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pathways regulated by both p53 and DACH1 (Fig. 1A,B). 
We next examined the proportion of genes regulated by 
both DACH1 and p53 at serial time points. A total of 
242, 2794, and 1621 DACH1-responsive genes were 
identified from the DACH1.0hr mRNA, DACH1.18h, and 
DACH1.36h datasets, respectively.  Of these genes, 20 out 
of 242, 129 out of 2794,  and 68 out of 1621 were also 
regulated by p53 (Fig. 1C). 
Figure 4: Subtype classification of breast cancer microarray samples. Heatmap depicting samples from combined breast cancer 
microarray datasets that were assigned to breast cancer gene expression subtypes. The ESR1 (ERα), epidermal growth factor receptor 2, 
(ErbB2) and progesterone receptor (PR) mRNA status is shown, together with relative abundance of DACH1, p21CIP1 (B) and RAD51 (C). 
The luminal (A and B) and basal breast cancer subtypes are outlined (red circle) for DACH1 vs. p21CIP1 or DACH1 vs. RAD51 abundance. 
A significant positive correlation between DACH1 and p21CIP1 is shown for luminal B (p=4x10-10) and basal breast cancer (p=1x10-10). A 
significant inverse correlation is shown for DACH1 and RAD51 in luminal A (p=1x10-10) and basal breast cancer (p<10-10). (D) A depiction 
of relative abundance of RAD51 and DACH1 for all breast cancer and (E) Kaplan-Meier plot showing differences in metastasis-free 
survival. The patients in which DACH1 and RAD51 expression remain inversely correlated showed improved survival (P<4.43x10-7).
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We next examined occupancy of p53 and DACH1 in 
the genome by comparing ChIP-Seq. Sets of genes bound 
by p53 and DACH1 in breast cancer cells were obtained 
from ChIP-Seq data [18, 19]. For gene annotation, high-
confidence ChIP-Seq regions were matched to the nearest 
proximal Ensemble gene identifier. A total of 1304 binding 
sites for p53 and 1844 binding sites for DACH1 were 
identified. 95 genes bound by both DACH1 and p53 were 
identified (p = 1.87 x 10-14, Fig. 1D, Table S1).  
Distributions of the locations of DACH1 and p53 
binding sites detected by ChIP-Seq demonstrated binding 
of active chromosomal regions proximal to gene coding 
regions, consistent with a model in which DACH1 and 
p53 localize to both very distal elements and promoter 
regulatory elements (Fig. 1E). The tag density profiles for 
p53 and DACH1 demonstrated a similar distribution of 
genomic association, comparing locations at the promoter, 
within a gene or downstream of the transcriptional stop 
site, with a relatively greater enrichment for p53 chipSeq 
peaks at more distal locations. A higher level resolution 
of relative binding in ChIP-Seq of p53 and DACH1 in 
relation to the transcriptional start site (TSS) confirmed 
this observation (Fig. 1F).  This may suggest that DACH1 
and p53 co-regulation occurs at distal regulatory sites. 
Figure 1G shows the tag density of DACH1 and p53 
chipSeq peaks relative to the coding regions of two co-
regulated genes, PARD6B and FAM84B.  These figures 
demonstrate that co-localization of DACH1 and p53 
occurs proximal to the promoter region for at least a subset 
of genes.
DACH1 enhances p53-mediated cell-cycle arrest 
and apoptosis. 
In order to examine the functional significance of 
p53 in DACH1-dependent function, MCF-7 cells were 
stably transduced with either DACH1 or a DACH1 
mutant that was defective in p53 binding (DACH1 ΔC) 
and then sequentially transduced with p53 shRNA (Fig. 
2). DACH1 inhibited cell proliferation assessed using 
the MTT assay. p53 shRNA increased proliferation, 
and the ability of DACH1 to inhibit proliferation was 
reduced by p53 shRNA (Fig. 2A). DACH1 expression 
reduced cellular proliferation, requiring the carboxyl 
terminus(Fig. 2B). shRNA to p53 abrogated DACH1 
repression, demonstrating the inhibition of proliferation 
by DACH1 is p53-dependent. To examine the role of the 
p53 binding domain of DACH1, the DACH1 carboxyl 
terminal deletion mutant (DACH1 ΔC) was deployed. 
WB was conducted of the cells to confirm the reduction of 
p53 levels with p53 shRNA and the levels of expression 
of DACH1 ΔC compared with DACH1 WT (Fig. 2C). 
DACH1 abundance assessed by the FLAG epitope showed 
similar levels of DACH1 WT vs. DACH1 ΔC. The p53 
shRNA treated cells showed reduced levels of p53 protein 
(Fig. 2C).
 The role of p53 in DACH1-mediated suppression 
of contact-dependent growth was assessed in MCF-7 
cells. p53 shRNA reduced DACH1-mediated inhibition 
of colony formation (Fig. 2D-F). Deletion of the DACH1 
carboxyl terminus reduced the inhibition of colony 
formation both in size and number (Fig. 2F-I). DACH1 
reduced the proportion of cells in the S-phase of the cell-
cycle, which was abolished by deletion of the DACH1 
carboxyl terminus. The inhibition of S-phase was p53-
dependent, as it was abrogated by p53 shRNA. DACH1 
expression induced the sub-G0 phase, requiring the 
DACH1 C-terminus and was abolished by p53 shRNA 
(Fig. 2K). The induction of apoptosis by DACH1 
assessed by Annexin V staining, also required the DACH1 
C-terminus and endogenous p53 (Fig. 2L). DACH1 
inhibited the proportion of cells in S-phase, which was 
abolished by deletion of the DACH1 C-terminus. p53 
shRNA abrogated the DACH1-mediated inhibition of 
S-phase.
NAD-dependent acetylation determines DACH1 
association with p53. 
Previous studies have demonstrated the physical 
association of DACH1 with the acetyl-transferase CBP 
[20], and in chromatin immunoprecipitation (ChIP) and 
WB, the association of DACH1 with SIRT1 and HDAC 
[6]. Collectively, these studies suggested a role for DACH1 
in binding to decetylases. In order to determine whether 
DACH1 could serve as a substrate for acetylates and 
decetylases, we conducted a mass spectrometry analysis 
of the DACH1 protein. LC/MS analysis of DACH1 after 
trypsin digestion identified peptides with high mascot 
scores. The panel of peptides mapped acetylation sites to 
residues Lysine 628. In order to determine whether lysine 
residue K628 within the 628-633 motif was acetylated, 
Edman-degradation analysis was conducted revealing 
acetylation, primarily of Lysine 628 (Fig. 3A). The 
DACH1 Lys 628 resembles a core acetylation motif found 
in p53 and nuclear receptors (Fig. 3B inset). 
In order to determine whether the association 
between DACH1 and p53 was regulated by NAD- or 
TSA-sensitive HDACs, cells were treated with either 
Nicotinamide (20 mM) or TSA (2 μM) for 8 hours. 
Immuno-precipitation was conducted using an antibody 
to p53 with subsequent WB to DACH1 (Fig. 3C). The 
addition of NAD enhanced DACH1 binding to p53, 
6-fold (Fig. 3C-E). In contrast, TSA reduced DACH1 
binding to p53 (Fig. 3C-E). The importance of HDAC in 
the association between endogenous DACH1 and p53 was 
determined in MDA-MB-231 cells. As observed in 293T 
cells, nicotinamide enhanced binding (2-fold) and TSA 
reduced binding (Fig. 3F, G).
In order to determine whether the DACH1 
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acetylated residue affected p53 association, point mutation 
was conducted of the acetylated residue and mammalian 
expression vectors for the point mutants that were co-
expressed with p53 in HEK293T cells.
DACH1 augments p53-dependent transcription of 
DNA damage and cell-cycle arrest genes. 
We next examined the functional significance of 
DACH1 on p53-dependent expression of the known 
target genes p21CIP1 and RAD51. p53 bound the p21CIP1 
regulatory region in ChIP-Seq. In MDA-MB-231 cells 
p21CIP1 was induced 1.6-fold and RAD51 was repressed 
3.3-fold. In MCF-7 cells p21CIP1 was induced 3-fold and 
RAD51 was repressed 1.8-fold. The DACH1-deficient 
MCF-7 cell line was used, in which DACH1 was stably 
transduced. In order to determine the mechanism by which 
DACH1 induced p21CIP1 and reduced RAD51 abundance, 
we examined the ability of DACH1 to regulate their 
transcription using the promotor-regulatory region of these 
two target genes assessed in luciferase reporter assays. 
DACH1 expression inhibited RAD51 reporter activity (S. 
4A). A DACH1 mutant deleted of the C-terminus failed to 
repress RAD51 reporter activity (S. 4B). 
p53 shRNA was used to stably reduce p53 levels 
in MCF-7 cells, in order to examine the re-expression of 
either p53 or a p53 mutant that evades defective DACH1 
binding. The re-expression of p53 enhanced p21CIP1 
promoter activity. Re-expression of the p53 mutant 
R248Q reduced p21CIP1 (S. 4C). DACH1 enhanced p53 wt 
dependent activity of the p21CIP1 promoter. Transduction 
of MCF-7 cells with the DACH1 binding defective mutant 
p53-R248Q mutant did not enhance p21CIP1 transcription 
and DACH1 did not affect p21CIP1 promoter activity in the 
presence of p53-R268Q, suggesting the effect of DACH1 
on p21CIP1 required p53 association. These findings are 
consistent with the observation that DACH1 is defective 
in binding the R248Q mutant. DACH1 enhancement of 
p53-dependent induction of p21CIP1 required the DACH1 
C-terminus (S. 4D). DACH1 expression was sufficient to 
induce the activity of multimeric p53-response element 
and deletion of the C-terminus reduced p53 activity 
~50% (S. 4E). DACH1 is known to bind a Forkhead like 
binding site [4]. DACH1 repression of a DACH1 response 
element in MCF-7 cells, an effect that was abrogated by 
p53 shRNA (S. 4E,F).
DACH1 and RAD51 expression are inversely 
correlated in Luminal A and Basal human breast 
cancer. 
In view of the finding that DACH1 induced p21CIP1 
and repressed RAD51, via p53, we investigated whether 
this gene expression relationship occurred in human 
breast cancer. We interrogated a data set of >2,250 
annotated human breast cancer samples (Fig. 4A). The 
relative abundance of DACH1 and p21CIP1 were compared 
amongst the five distinct mRNA subtypes of human breast 
cancer (Fig. 4B). Consistent with the finding that DACH1 
induced p21CIP1 via p53, DACH1 and p21CIP1 abundance 
was positively correlated in luminal B (p = 4x10-10) and 
basal breast cancer (p<10-10)(Fig. 4C). Furthermore, when 
all breast cancer tumor types were considered together, 
patients with tumors in which DACH1 expression was 
increased with a corresponding decrease in RAD51 levels 
(red square Fig. 4D), had improved relapse-free survival 
in Kaplan-Meier analysis (Fig. 4E).
DISCUSSION 
The studies reported here demonstrate that p53 
binds to the cell-fate determination factor, DACH1. 
Mutational analysis demonstrated the specificity of 
binding by identifying the carboxyl terminus of DACH1 
and key amino acids of p53 required for binding. p53 
mutations occur in ~25% of human breast cancer. Herein, 
the p53-P72R and p53-R273H evaded DACH1 binding. 
The p53 polymorphism P72R showed reduced DACH1 
binding. The P72R polymorphism occurs in a proline 
rich region of p53 known to be important for growth 
suppression and apoptotic functions [19]. The P72R 
showed reduced ability to induce programmed cell death 
and reduced ubiquitination and nuclear export [21-23]. 
The R248Q and R273H are hot spot mutations that arise 
in human cancer and are classified as a “contact” mutant, 
in which the overall architecture of the DBD is retained, 
but critical DNA contact points are lost [24]. DACH1 
inhibits metastasis and R273H mutant knock-in mice 
show increased metastasis [25], raising the possibility that 
evasion of DACH1 binding may contribute to the “gain 
of function” by the R273H mutant. The cell-cycle arrest 
phenotype of p53 depends on the ability to induce the 
transcription of p21. Herein, DACH1 inhibition of S-phase 
and p21 transcription required p53 and the C-terminal 
DACH1 p53 binding domain.
DACH1 induced apoptosis via p53. The ability of 
p53 to induce apoptosis plays an important role in tumor 
suppression [26, 27]. The induction of apoptosis by p53 
involves a distinct class of genes, including BAX, PUMA, 
NOXA and PIG3, which were also induced by DACH1 
[17]. Given that a significant proportion of genes bind 
both DACH1 and p53 in ChIP-Seq, the mechanism by 
which DACH1 enhances p53-dependent function may 
involve induction of common target genes through either 
common or distinct CIS elements. DACH1 was capable of 
enhancing both DACH1 activity through the FOXO-like 
element and via p53 dependent transactivation.
Herein, the NAD-dependent HDAC, deacetylase 
SIRT1 enhanced DACH1/p53 association. DACH1 
enhanced p53-dependent transactivation and DACH1-
dependent transcription via a DACH1 response element 
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in a p53-dependent manner. Thus, DACH1/p53 forms 
a signaling module, which is augmented by SIRT1. 
Acetylation of p53 can negatively regulate protein-protein 
interactions, and unacetylated p53 binds more strongly 
to Mdm2 and Mdmx [11]. The DACH1/p53 module is 
characterized by overlapping gene sets and function. 
DACH1 was shown to be acetylated, with K628 being 
identified by LC/MS and Edman degradation. Mutation 
of DACH1 K628 to create residues that could not gain 
an acetyl group, enhanced p53 binding. DACH1 showed 
enhanced binding to p53-K120R. In contrast, mutation 
of the carboxyl-terminal nine lysine residues, abolished 
p53-dependent induction of p21 without  affecting 
MDM2 binding. The K120R mutant is competent for cell-
cycle arrest and binding to p21 and hMDM2 promoters, 
while being defective for apoptosis [14, 16]. p53 K120 
is acetylated via Tip60/hMOF and is a recurrent target 
for mutation during tumor development [14, 28]. These 
findings are consistent with a model in which distinct 
p53 lysine residues coordinate dissociable functions and 
suggest that the DACH1/p53 module engages K120 [29, 
30]. As SIRT1 is known to bind p53 in the nucleus and 
deacetylate p53 at least at K382 and considering this 
residue is also deacetylated by HDAC [31], it would be 
of interest to determine whether the reduction in p53 
associated with DACH1 in NAM with TSA correlates 
with an increase in acetylated p53 at K382. Treatment 
with the SIRT inhibitor nicotinamide enhanced the relative 
amount of DACH1 bound to p53, whereas the HDAC I 
and II inhibitor, TSA, did not. These findings suggest 
NAD-dependent deacetylation of DACH1 augments p53 
association.
The decreased bindings of DACH1 to the p53 
phosphorylation defective mutants are consistent with 
prior findings that DACH1 associates with CBP [20]. 
Phosphorylation of amino-terminal sites in p53, including 
Ser15 and Ser20, increases the association of p53 with 
p300/CBP and stimulates p53 transactivation [32, 33]. 
Phosphorylation of Ser15 is necessary for sequential 
modification, including acetylation of lysine residues in 
the p53 DBD and carboxyl terminal domains (reviewed 
in [33]). Phosphorylation of these residues also reduces 
MDM2 binding [34]. As Ser15 serves at the distal arm 
of DNA damage and stress signaling pathways, along 
with ATM/ATR and DNA-PK [35, 36], these studies 
raise the possibility that DACH1 may function to inhibit 
DNA damage signaling. It will be of interest to determine 
whether DACH1 is capable of inhibiting other DNA 
damage signaling pathways, such as phosphorylation of 
H2AX.
MATERIALS AND METHODS
Immunohistochemistry 
Immuno-histochemical analysis of human breast 
cancer cell lines was conducted using a polyclonal 
DACH1 antibody [7].
Cell culture, plasmid construction, reporter 
genes, expression vectors, DNA transfection, and 
luciferase assays 
Cell culture, DNA transfection, and luciferase 
assays using the Rad51-Luc and p21-Luc reporter 
genes were performed as previously described [37]. The 
HEK293T, MDA-MB-453, MDA-MB-231 and SKBR3 
HEK293T cells were cultured in DMEM supplemented 
with 10% fetal calf serum, 1% penicillin, and 1% 
streptomycin and were previously described [7]. The 
expression plasmids encoding an N-terminal FLAG 
peptide linked to DACH1 or DACH1 deleted of the DNA 
binding domain (ΔDS) were previously described [4]. The 
expression vector encoding the DACH1 alternate splice 
forms were sub-cloned into p3xFLAG-CMV-10 vector 
(Sigma). The expression vectors encoding wildtype or 
mutant p53 in the vector pLKO.1 (shp53 sequence: 5’ 
– AAACCCAGGGCTGCCTTGGAAAAG – 3’) p53 
shRNA expression vector were previously described 
[14, 38]. p53 shRNA transfection and infection followed 
standard protocols [5,6,7]. GFP positive cells were 
selected by FACS. Cells were plated at a density of 1 x 
105 cells in a 24-well plate on the day prior to transfection 
with Superfect according to the manufacturer’s protocol 
(Qiagen, Valencia, CA). A dose-response was determined 
in each experiment with 50 and 200 ng of expression 
vector and the promoter reporter plasmids (0.5 μg). 
Luciferase activity was normalized for transfection 
efficiency using β-galactosidase reporters as an internal 
control. The -fold effect of expression vector was 
determined with comparison to the effect of the empty 
expression vector cassette and statistical analyses were 
performed using the t- test. 
Cell Proliferation Assays 
Cells infected with MSCV-IRES-GFP, MSCV-
DACH1-IRES-GFP, MSCV-DACH1ΔC or C-term-
IRES-GFP, were seeded into 96 well plates in normal 
growth medium, and cell growth was measured daily 
by MTT assays using 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide.
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Colony forming assays 
4 x 103 cells were plated in triplicate in 3 ml of 0.3% 
agarose (sea plaque) in complete growth medium in the 
presence or absence of 2 µg/ml doxycycline overlaid on 
a 0.5% agarose base, also in complete growth medium. 
2 weeks after incubation, colonies more than 50 µm in 
diameter were counted using an Omnicon 3600 image 
analysis system. The colonies were visualized after 
staining with 0.04% crystal violet in methanol for 1 to 2 h.
Identification of DACH1 phosphorylation and 
acetylation sites by mass spectrometry and Edman 
degradation assays. Phosphopeptide mapping 
DACH1 protein was isolated by immunoprecipitation 
and separated by gel electrophoresis.  The gels were 
stained with Coomassie G250 and the bands were excised 
and digested with trypsin.  Phosphorylated peptides 
were isolated using affinity purification using TiO2 Nu-
tips from Glygen.  Briefly, the extracted peptides were 
loaded on the tip in a buffer containing 300 mg/ml DHB 
in 80% Acetonitrile, 0.1% TFA, washed once with the 
loading buffer and once with 80% Acetonitrile, 0.1% TFA 
and eluted in 0.4M Ammonium Hydroxide.  Peptides 
were immediately acidified with Formic Acid and 
were analyzed by ESI-MS/MS on a Thermo-Electron 
ProteomeX LC/MS workstation as previously described 
[39]. Spectra were searched against the Swissprot database 
using Mascot (Matrix Science) with Carbamidomethyl as 
a fixed modification and Oxidation (M), Phospho (ST), 
Phospho (Y) as variable modifications. Peptides that 
had a score greater than 45 were reported as statistically 
significant (p<0.05) [40].
Dehydrated peptides were re-suspended in 5% 
acetonitrile, 0.05% formic acid and immediately loaded 
on a nano-spray tip for LC-MS/MS analysis. 10 - 
15% of the peptide digest is loaded on a Magic C18 
AQ (Michrom) nanospray tip, packed to 5 cm. This 
tip was loaded, using a pressure bomb, and washed, 
after installation on the HPLC of a Thermo LTQ mass 
spectrometer, with 5% methanol, 0.1% formic acid, 
for 10 min with a flow rate of 600 nl/minute (about 10 
column volumes = 6.6 µl) The peptides were eluted and 
analyzed in an LC-MS/MS run, using a  5-15% methanol 
gradient over 2.5 minutes, followed by a 15-60% methanol 
gradient for 67 minutes, a 60% methanol isocratic step of 4 
minutes, ending with a 3-minute 95% methanol step, with 
all solvents containing 0.1% formic acid. A full MS survey 
scan was performed every 3 seconds and the top 7 peaks 
were selected to produce MS/MS fragmentation spectrum. 
To increase coverage of basic peptides, chymotrypsin 
digests were also applied to an LC-MS/MS run at neutral 
pH in 20 mM ammonium format, instead of 0.1% formic 
acid, using an identical gradient elution program and mass 
spectrometry run, as above.
Mapping of proteolytic peptide fragments 
and acetylation sites
The MS and MS/MS fragmentation spectrum 
data were used in a Mascot search of the whole 
human proteome. To identify peptide sequences modified 
with acetyl groups, a custom database, containing the 
recombinant DACH1 sequence, was also searched. 
The following search criteria were used for selecting 
fragmentation spectra that map to proteolytic peptides: 
peptide tolerance = -0.8 to +0.5, a minimum ion score of 
15, and a fragmentation spectrum, containing fragment 
ions that either include or flank the acetylated amino acid 
position. Mascot searches were conducted, allowing for 
multiple positive charge-states, 2, 3, or 4 missed cleavage 
sites, fixed S-carboxyamidomethyl modification of 
cysteine and variable methionine oxidation and lysine 
acetylation.
Edman degradation assays were conducted using 
an acetylated DACH1 peptide. The synthetic peptide 
corresponding to the DACH1 (residues a.a. 626-644, NH2-
VQK RLK KEK KAK RKL QEAL-COOH) that contains 
lysine-rich motif was synthesized by Bio·Synthesis 
(Lewisville, TX) and purified to 95% purity by HPLC. 
The peptides were acetylated in vitro by incubation with 
5 mM acetyl-CoA and baculovirus-purified FLAG-p300 
at 30°C for 2h. After incubation, acetylated peptides were 
separated from contaminating p300 by passage through 
a micron filter (Amicon Inc., Beverly, MA) and further 
purified by analytical reversed phase HPLC. The reaction 
products were analyzed with a PE-Biosystems DE-STR 
MALDI-TOF mass spectrometer. Further analysis by 
Edman degradation was performed on a PE-Biosystems 
Procise sequencer and Phenylthiohydantoin-acetyl-lysine 
was measured by absorbance at 259 nm. 
Cell Cycle Analysis 
Cell cycle parameters were determined using laser 
scanning cytometry. Cells were processed by standard 
methods using propidium iodide staining of cell DNA. 
Each sample was analyzed by flow cytometry with a 
FACScan Flow Cytometer (Becton-Dickinson Biosciences, 
Mansfield, MA) using a 488 nm laser. Histograms were 
analyzed for cell cycle compartments using ModFit version 
2.0 (Verity Software House, Topsham, ME). A minimum 
of 20,000 events was collected to maximize statistical 
validity of the compartmental analysis. Apoptosis was 
determined by Annexin V staining [41].  
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Immunoprecipitation and Western Blot 
Immunoprecipitation (IP) and Western blot assays 
were performed in HEK293T cells as indicated. Cells were 
pelleted and lysed in buffer (50 mM HEPES, pH 7.2, 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% 
Tween 20) supplemented with a protease inhibitor cocktail 
(Roche Diagnostics, Mannheim, Germany). Antibodies 
used for IP and Western blot were: anti-p53 (SC-126) and 
anti-FLAG (M2 clone, Sigma). 
Microarray and Cluster Analysis 
DNA-free total RNA isolated from DACH1 
inducible MDA-MB-231 cells were used to probe human 
OneArray (Phalanx). RNA quality was determined by gel 
electrophoresis. Analysis of the arrays was performed 
using GeneSpring. Arrays were normalized using robust 
multi-array analysis, and the p value of 0.05 was applied 
as a statistical criterion for differentially expressed 
genes. These genes were then grouped using hierarchical 
clustering with “complete” agglomeration, and each cluster 
was further analyzed based upon the known function of 
the genes contained in the cluster. Expression profiles are 
displayed using Treeview. Classification and clustering for 
pathway level analysis were performed by using gene sets 
ASSESS (Analysis of Sample Set Enrichment Scores), and 
DAVID available on line. ASSESS provides a measure of 
enrichment of each gene set in each sample.
Genomic occupancy of DACH1 and p53. 
Identification of genes with DACH1 and p53 
binding sites 
Binding sites for p53 in breast cancer cells 
were obtained from a ChIP-Seq analysis of chromatin 
occupancy by p53 following activation by three different 
molecules, nutlin3a, RITA and 5-fluorouracil (5-FU) 
[18]. High-confidence ChIP-Seq peaks were identified 
as described [18] by applying the following filters: 
p≤0.05, ≥2 fold enrichment over IgG control, peak area 
≥20. The intersections of peaks identified from the three 
p53 inducing treatments were used as p53 binding sites. 
DACH1 binding sites were identified from ChIP-Seq of a 
breast cancer cell line stably expressing DACH1 [4]. ChIP-
Seq peaks were mapped to the nearest proximal Ensemble 
gene identifier.  Significant overlap in p53 and DACH1 
regulated genes was tested using the hypergeometric 
distribution with all ensemble gene identifiers in homo 
sapiens used as a reference set.  Annotation of the location 
of ChIP-Seq peaks relative to gene coding regions was 
facilitated by the ChIPpeakAnno and GenomicRanges 
packages in Bioconductor. The Integrated Genome 
Browser software package was used for visualization of 
ChIP-seq tag density relative to gene coding regions. 
Identification of genes regulated by DACH1. 
Genes regulated by DACH1 were also identified 
from gene expression microarray experiments. In the 
first experiment, gene expression was measured in MDA-
MB-231 cells engineered to express DACH1 and treated 
with either vehicle or ponasterone A for 18 and 36 hours. 
Differentially expressed genes were identified as genes 
with a 1.5 fold-change on average in ponasterone A 
treated vs. control DACH1-inducible MDA-MB-231 cells. 
Affymetrix probe set identifiers were mapped to Ensemble 
gene identifiers using information from Affymetrix 
annotation files. Significant overlap in p53- and DACH1- 
regulated genes was tested using the hypergeometric 
distribution with all Ensemble gene identifiers annotated 
on the Affymetrix chip as a reference set.  In order 
to identify signaling pathways enriched with p53- or 
DACH1-regulated genes, the hypergeometric test was 
used with pathway gene sets derived from the molecular 
signatures database.
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